Endemic eastern equine encephalitis in the Amazon region of Peru

Patricia Aguilar, Rebecca M. Robich, Michael J. Turell, Monica L. O'Guinn, Terry A. Klein, Alfredo Huaman, Carolina Guevara, Zonia Rios, Robert B. Tesh, Douglas M. Watts, James Olson, Scott Weaver

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Eastern equine encephalitis virus (EEEV) causes severe neurologic disease in North America, but only two fatal human cases have been documented in South America. To test the hypothesis that alphavirus heterologous antibodies cross-protect, animals were vaccinated against other alphaviruses and challenged up to 3 months later with EEEV. Short-lived cross-protection was detected, even in the absence of cross-neutralizing antibodies. To assess exposure to EEEV in Peru, sera from acutely ill and healthy persons were tested for EEEV and other alphavirus antibodies, as well as for virus isolation. No EEEV was isolated from patients living in an EEEV-enzootic area, and only 2% of individuals with febrile illness had EEEV-reactive IgM. Only 3% of healthy persons from the enzootic region had EEEV-neutralizing antibodies. Our results suggest that humans are exposed but do not develop apparent infection with EEEV because of poor infectivity and/or avirulence of South American strains.

Original languageEnglish (US)
Pages (from-to)293-298
Number of pages6
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume76
Issue number2
StatePublished - Feb 2007

Fingerprint

Eastern Equine Encephalomyelitis
Eastern equine encephalitis virus
Peru
Alphavirus
Neutralizing Antibodies
Cross Protection
Heterophile Antibodies
South America
North America
Nervous System Diseases
Immunoglobulin M
Fever

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases

Cite this

Aguilar, P., Robich, R. M., Turell, M. J., O'Guinn, M. L., Klein, T. A., Huaman, A., ... Weaver, S. (2007). Endemic eastern equine encephalitis in the Amazon region of Peru. American Journal of Tropical Medicine and Hygiene, 76(2), 293-298.

Endemic eastern equine encephalitis in the Amazon region of Peru. / Aguilar, Patricia; Robich, Rebecca M.; Turell, Michael J.; O'Guinn, Monica L.; Klein, Terry A.; Huaman, Alfredo; Guevara, Carolina; Rios, Zonia; Tesh, Robert B.; Watts, Douglas M.; Olson, James; Weaver, Scott.

In: American Journal of Tropical Medicine and Hygiene, Vol. 76, No. 2, 02.2007, p. 293-298.

Research output: Contribution to journalArticle

Aguilar, P, Robich, RM, Turell, MJ, O'Guinn, ML, Klein, TA, Huaman, A, Guevara, C, Rios, Z, Tesh, RB, Watts, DM, Olson, J & Weaver, S 2007, 'Endemic eastern equine encephalitis in the Amazon region of Peru', American Journal of Tropical Medicine and Hygiene, vol. 76, no. 2, pp. 293-298.
Aguilar P, Robich RM, Turell MJ, O'Guinn ML, Klein TA, Huaman A et al. Endemic eastern equine encephalitis in the Amazon region of Peru. American Journal of Tropical Medicine and Hygiene. 2007 Feb;76(2):293-298.
Aguilar, Patricia ; Robich, Rebecca M. ; Turell, Michael J. ; O'Guinn, Monica L. ; Klein, Terry A. ; Huaman, Alfredo ; Guevara, Carolina ; Rios, Zonia ; Tesh, Robert B. ; Watts, Douglas M. ; Olson, James ; Weaver, Scott. / Endemic eastern equine encephalitis in the Amazon region of Peru. In: American Journal of Tropical Medicine and Hygiene. 2007 ; Vol. 76, No. 2. pp. 293-298.
@article{76c8103c2f184512afab1ab22644beb7,
title = "Endemic eastern equine encephalitis in the Amazon region of Peru",
abstract = "Eastern equine encephalitis virus (EEEV) causes severe neurologic disease in North America, but only two fatal human cases have been documented in South America. To test the hypothesis that alphavirus heterologous antibodies cross-protect, animals were vaccinated against other alphaviruses and challenged up to 3 months later with EEEV. Short-lived cross-protection was detected, even in the absence of cross-neutralizing antibodies. To assess exposure to EEEV in Peru, sera from acutely ill and healthy persons were tested for EEEV and other alphavirus antibodies, as well as for virus isolation. No EEEV was isolated from patients living in an EEEV-enzootic area, and only 2{\%} of individuals with febrile illness had EEEV-reactive IgM. Only 3{\%} of healthy persons from the enzootic region had EEEV-neutralizing antibodies. Our results suggest that humans are exposed but do not develop apparent infection with EEEV because of poor infectivity and/or avirulence of South American strains.",
author = "Patricia Aguilar and Robich, {Rebecca M.} and Turell, {Michael J.} and O'Guinn, {Monica L.} and Klein, {Terry A.} and Alfredo Huaman and Carolina Guevara and Zonia Rios and Tesh, {Robert B.} and Watts, {Douglas M.} and James Olson and Scott Weaver",
year = "2007",
month = "2",
language = "English (US)",
volume = "76",
pages = "293--298",
journal = "American Journal of Tropical Medicine and Hygiene",
issn = "0002-9637",
publisher = "American Society of Tropical Medicine and Hygiene",
number = "2",

}

TY - JOUR

T1 - Endemic eastern equine encephalitis in the Amazon region of Peru

AU - Aguilar, Patricia

AU - Robich, Rebecca M.

AU - Turell, Michael J.

AU - O'Guinn, Monica L.

AU - Klein, Terry A.

AU - Huaman, Alfredo

AU - Guevara, Carolina

AU - Rios, Zonia

AU - Tesh, Robert B.

AU - Watts, Douglas M.

AU - Olson, James

AU - Weaver, Scott

PY - 2007/2

Y1 - 2007/2

N2 - Eastern equine encephalitis virus (EEEV) causes severe neurologic disease in North America, but only two fatal human cases have been documented in South America. To test the hypothesis that alphavirus heterologous antibodies cross-protect, animals were vaccinated against other alphaviruses and challenged up to 3 months later with EEEV. Short-lived cross-protection was detected, even in the absence of cross-neutralizing antibodies. To assess exposure to EEEV in Peru, sera from acutely ill and healthy persons were tested for EEEV and other alphavirus antibodies, as well as for virus isolation. No EEEV was isolated from patients living in an EEEV-enzootic area, and only 2% of individuals with febrile illness had EEEV-reactive IgM. Only 3% of healthy persons from the enzootic region had EEEV-neutralizing antibodies. Our results suggest that humans are exposed but do not develop apparent infection with EEEV because of poor infectivity and/or avirulence of South American strains.

AB - Eastern equine encephalitis virus (EEEV) causes severe neurologic disease in North America, but only two fatal human cases have been documented in South America. To test the hypothesis that alphavirus heterologous antibodies cross-protect, animals were vaccinated against other alphaviruses and challenged up to 3 months later with EEEV. Short-lived cross-protection was detected, even in the absence of cross-neutralizing antibodies. To assess exposure to EEEV in Peru, sera from acutely ill and healthy persons were tested for EEEV and other alphavirus antibodies, as well as for virus isolation. No EEEV was isolated from patients living in an EEEV-enzootic area, and only 2% of individuals with febrile illness had EEEV-reactive IgM. Only 3% of healthy persons from the enzootic region had EEEV-neutralizing antibodies. Our results suggest that humans are exposed but do not develop apparent infection with EEEV because of poor infectivity and/or avirulence of South American strains.

UR - http://www.scopus.com/inward/record.url?scp=34047150819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047150819&partnerID=8YFLogxK

M3 - Article

VL - 76

SP - 293

EP - 298

JO - American Journal of Tropical Medicine and Hygiene

JF - American Journal of Tropical Medicine and Hygiene

SN - 0002-9637

IS - 2

ER -